Odense C

• Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) Ended
  2023-508105-24-00 5 2021-11-11 COVID-19
• A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended
  2023-506897-11-00 5 2021-10-18 Non-diabetic chronic kidney disease
• Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA … Ended
  2023-506961-74-00 4 2021-08-31 Non-alcoholic steatohepatitis (NASH)
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended
  2022-501342-29-00 5 2021-07-21 Esophageal Carcinoma
• MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non … Ended
  2022-501252-28-00 4 2021-04-15 Non Small Cell Lung cancer
• A Study to Evaluate Effects of RO7121661 and RO7247669 Compared With Nivolumab in Advanced or Metastatic Squamous Cell Carcinoma of the Esop … Ended
  2024-511403-41-00 4 2021-04-14 Advanced or metastatic squamous cell carcinoma of the esophagus
• A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended
  2023-505273-33-00 5 2021-02-15 "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple My … Ended
  2023-504571-25-00 3 2020-10-20 Relapsed or Refractory Multiple Myeloma
• Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery Ended
  2024-511171-15-00 3 2020-07-06 Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
• Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended
  2023-507024-24-00 5 2020-05-05 Metastatic hormone sensitive prostate cancer
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2023-508364-29-00 5 2019-11-22 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 5 2018-12-05 Gastric and gastric esophageal junction (GEJ) adenocarcinoma
• Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) Ended
  2024-515748-22-01 5 2018-12-01 Myocardinal infarction
• KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study Ended
  2024-511714-20-00 4 2018-01-30 Multiple Myeloma
• Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of pr … Ended
  2023-510200-42-00 5 2017-12-06 primary sclerosing cholangitis (PSC)

Showing 433–456 of 467 trials